Alkem Laboratories Ltd
Alkem Laboratories Ltd (ALKEM) last traded at ₹5,347, a market capitalisation of ₹63,931 crore, on a P/E of 28.1. Over the past 52 weeks the stock has ranged between ₹5,075 and ₹5,934. Alkem Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹3,740 crore and net profit of ₹521 crore. Figures are as of 25 Aug 2026 and are not real time.
Alkem Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Alkem Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹3,740 cr, up 10.9% from ₹3,371 cr a year earlier. Net profit was ₹521 cr, down 22.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating profit | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 22% | 23% | 12% | 22% | 23% | 22% | 14% | 20% |
| Other income | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 10% | 12% | 18% | 13% | 13% | 16% | 40% | 32% |
| Net profit | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS (₹) | 57.60 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 | 43.49 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Alkem Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 | 15,081 |
| Operating profit | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 3,007 | 3,032 |
| OPM % | 22% | 19% | 14% | 18% | 19% | 20% | 20% |
| Net profit | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 | 2,204 |
| EPS (₹) | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 192.51 | 180.45 |
TTM is the trailing twelve months to the most recent quarter.
Alkem Laboratories Ltd growth and returns
- 10 Years
- 12%
- 5 Years
- 11%
- 3 Years
- 8%
- TTM
- 13%
- 10 Years
- 12%
- 5 Years
- 9%
- 3 Years
- 32%
- TTM
- 0%
- 10 Years
- 13%
- 5 Years
- 7%
- 3 Years
- 13%
- 1 Year
- -1%
- 10 Years
- 18%
- 5 Years
- 18%
- 3 Years
- 19%
- Last Year
- 19%
Alkem Laboratories Ltd shareholding pattern
Promoters held 49.70% at Jun 2026, down from 53.04% at Jun 2025. FIIs 10.42% and DIIs 22.64%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.66% | 55.66% | 55.13% | 53.04% | 51.20% | 51.20% | 51.20% | 49.70% |
| FIIs | 9.02% | 10.14% | 9.40% | 9.11% | 9.47% | 9.97% | 10.15% | 10.42% |
| DIIs | 19.21% | 18.01% | 19.42% | 21.80% | 21.93% | 21.54% | 21.39% | 22.64% |
| Public | 16.12% | 16.19% | 16.05% | 16.05% | 17.39% | 17.30% | 17.25% | 17.25% |
| No. of shareholders | 74,744 | 84,038 | 84,326 | 79,740 | 67,196 | 64,536 | 62,835 | 62,822 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Alkem Laboratories Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Earnings Call TranscriptCompany Updatemedium impact
Cruxal's analysis: Alkem Laboratories reported Q1 FY2027 revenue of INR 3,740 crore, reflecting 11% YoY…
Read the full analysis - Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingAGM/EGMlow impact
Cruxal's analysis: Alkem Laboratories Limited has successfully secured shareholder approval for the scheme…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has fulfilled its regulatory obligation under Regulation 30 of the…
Read the full analysis - With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q1FY27 Earnings Conference Call'' is available ....Company Updatelow impact
Cruxal's analysis: Alkem Laboratories Limited has formally submitted the audio recording of its Q1FY2027…
Read the full analysis - The Financials Results of the Company for the quarter ended 30th June, 2026 having been communicated to the Stock Exchanges today ie 14th Aug the trading window shall open on 17th Aug, 2026.Insider Trading / SASTlow impact
- Pl find enclosed press release and analyst presentation on Q1FY27 earnings and business updates of the CompanyCompany Updatehigh impact
Cruxal's analysis: Alkem Laboratories reported Q1 FY27 total revenue from operations of 3,740 crore…
Read the full analysis - Pl find attached herewith intimation under Reg 30Company Updatelow impact
Cruxal's analysis: Alkem Laboratories has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Pl find enclosed unaudited financial results along with LRR for quarter ended 30th June, 2026Resulthigh impact
Cruxal's analysis: Alkem Laboratories reported Q1 FY27 consolidated revenue of 3,740 crore, reflecting a…
Read the full analysis - Board Meeting Outcome for Outcome Of Board Meeting Dated 14/08/2026Board Meetinghigh impact
Cruxal's analysis: Alkem Laboratories Limited reported consolidated revenue from operations of 3,740.15…
Read the full analysis - Update On US FDA Inspection At Company'S Manufacturing Facility Located At Amaliya, DamanCompany Updatelow impact
Cruxal's analysis: Alkem Laboratories has issued a formal intimation regarding the status of a US FDA…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Alkem Laboratories Ltd
Cruxal reads every Alkem Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.